-
Mashup Score: 1
Fred Saad joins Alicia Morgans in a discussion focusing on the biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). This updated analysis provides more detail on patients with HRR mutations in the PROpel trial. In this…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2
Fred Saad joins Alicia Morgans in a discussion focusing on the biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). This updated analysis provides more detail on patients with HRR mutations in the PROpel trial. In this…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
rPFS improvement regardless of mutations in biomarker subgroups in the phase III #PROpel trial in first-line therapy for patients with #mCRPC. Fred Saad, MD, FRCS @chumontreal joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/hAu7MSJDeL https://t.co/7UBAzFOX2I
-
-
Mashup Score: 1
Fred Saad joins Alicia Morgans in a discussion focusing on the biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). This updated analysis provides more detail on patients with HRR mutations in the PROpel trial. In this…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
rPFS improvement regardless of mutations in biomarker subgroups in the phase III #PROpel trial in first-line therapy for patients with #mCRPC. Fred Saad, MD, FRCS @chumontreal joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/hAu7MSJDeL https://t.co/xkqbbv6LUS
-
-
Mashup Score: 4The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo - 2 year(s) ago
Elena Castro and Joaquin Mateo join Alicia Morgans in a conversation on data related to genetic testing, PARP inhibitors, and the data we saw come out of GU ASCO with the PROpel and MAGNITUDE trials and they discuss how this data impacts the use of PARP inhibitors in castrate-resistant prostate cancer (CRPC). Drs. Castro, Mateo, and Morgans discuss this data in terms of next-generation…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The use of PARP inhibitors in castrate-resistant #ProstateCancer. @Ecastromarcos & @quimmateo joins @CaPsurvivorship @DanaFarber to discuss, genetic testing, PARP inhibitors, and data from the #PROpel and #MAGNITUDE trials. #WatchNow > https://t.co/vkfqp3ekEH @APCCC_Lugano https://t.co/jGLLL1W7Mq
-
-
Mashup Score: 2PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad - 2 year(s) ago
Drs Maha Hussain and Fred Saad join Dr Alicia Morgans in a conversation on PARP combination therapy in prostate cancer and the status of its use in clinical practice. In this context, the group discusses the PROpel and the MAGNITUDE studies data and how the data can be used in clinical practice. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
PARPi combination therapy use in clinical practice - Ready for prime-time? Maha Hussain @LurieCancer and Fred Saad @chumontreal join @CaPsurvivorship @DanaFarber in a conversation on the #PROpel and the #MAGNITUDE study data. #WatchNow > https://t.co/3SiEZnfZeO @APCCC_Lugano https://t.co/H0ZoT7jYqR
-
-
Mashup Score: 0The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo - 2 year(s) ago
Elena Castro and Joaquin Mateo join Alicia Morgans in a conversation on data related to genetic testing, PARP inhibitors, and the data we saw come out of GU ASCO with the PROpel and MAGNITUDE trials and they discuss how this data impacts the use of PARP inhibitors in castrate-resistant prostate cancer (CRPC). Drs. Castro, Mateo, and Morgans discuss this data in terms of next-generation…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
The use of PARP inhibitors in castrate-resistant #ProstateCancer. @Ecastromarcos & @quimmateo joins @CaPsurvivorship @DanaFarber to discuss, genetic testing, PARP inhibitors, and data from the #PROpel and #MAGNITUDE trials. #WatchNow > https://t.co/vkfqp2WJg7 @APCCC_Lugano https://t.co/1nVY5yKgc1
-
-
Mashup Score: 0PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad - 2 year(s) ago
Drs Maha Hussain and Fred Saad join Dr Alicia Morgans in a conversation on PARP combination therapy in prostate cancer and the status of its use in clinical practice. In this context, the group discusses the PROpel and the MAGNITUDE studies data and how the data can be used in clinical practice. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
PARPi combination therapy use in clinical practice - Ready for prime-time? Maha Hussain @LurieCancer and Fred Saad @chumontreal join @CaPsurvivorship @DanaFarber in a conversation on the #PROpel and the #MAGNITUDE study data. #WatchNow > https://t.co/3SiEZmYWcO @APCCC_Lugano https://t.co/zRCGKnwFC6
-
-
Mashup Score: 2
ESMO 2022 assessing tumor tissue-based and circulating tumor DNA ctDNA in the PROpel trial, the PROpel trial in metastatic castrate-resistant prostate cancer, homologous recombination repair in patients enrolled in the Phase III PROpel trial
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Detection of mutations in homologous recombination repair genes in tumor tissue and circulating tumor DNA from patients with #mCRPC in the phase III #PROpel trial. Presented by @AarmstrongDuke @DukeCancer. #ESMO22 written coverage by @WallisCJD @UofT > https://t.co/K7lyIEqjoJ https://t.co/stzqFBecQm
-
-
Mashup Score: 1ESMO 2022: Discussion of PRESTO in High-Risk Biochemically Relapsed Prostate Cancer and PROpel in mCRPC - 2 year(s) ago
ESMO 2022 Discussion on PROpel, Discussion on PRESTO, PRESTO Androgen Annihilation in Patients with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19), Biomarker Analysis and Updated Results from the Phase III PROpel Trial of Abiraterone and Olaparib vs Abiraterone and Placebo as First-Line Therapy for Patients with mCRPC
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
A discussion of #PRESTO in high-risk biochemically relapsed #ProstateCancer and #PROpel in #mCRPC. Presentation by @jodebon @royalmarsdenNHS. #ESMO22 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/oAjHbe7W5e @myESMO https://t.co/4Kh8JHeauS
-
-
Mashup Score: 10
ESMO 2022 PROpel, biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with mCRPC
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Biomarker analysis and updated results from the phase III #PROpel trial of abiraterone and olaparib vs abiraterone and PBO as 1L therapy for patients with #mCRPC. Presented by Fred Saad, MD, FRCS @chumontreal. #ESMO22 coverage by @zklaassen_md > https://t.co/xx9oLU9H7m @myESMO https://t.co/2J4vIuryM1
-
rPFS improvement regardless of mutations in biomarker subgroups in the phase III #PROpel trial in first-line therapy for patients with #mCRPC. Fred Saad, MD, FRCS @chumontreal joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/hAu7MSJDeL https://t.co/udty8BYQGc